Company intelligence / Profile preview

ASK Health

Research Triangle Park, North Carolina, USAaskhealth.org ↗

Ownership: Private
Development stage: Other

Overview

AskBio has published complete results from a Phase 1b trial of AB-1005, an investigational GDNF gene therapy for Parkinson’s disease. The treatment was well tolerated with no serious adverse events related to GDNF gene therapy in all participants. Clinical assessments showed stability or improvement in motor function at 18 months post-gene transfer

Therapeutic areas: Neurology
Modalities: Gene therapyAdeno-associated virus (AAV) vector-based gene therapyBiologic
Industry: Biotech

Partnerships

Bayer AG (as parent)extensive global research collaborations mentioned but not named specifically

Beyond the preview

Go deeper on ASK Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASK Health.

Explore the full profile